Allan Jordan, Head of Chemistry for the Drug Discovery Unit of CRUK (Cancer Research U.K.)
0:00 CRUK - The world’s largest single disease research charity
4:11 Flexibility to do more early stage drug discovery
9:14 Partnering with the NHS on basket trials
13:53 Skeptics of precision medicine
19:35 Impact of Brexit
Let’s take a break from the US and head over to the UK, home of the world’s largest single disease medical research charity.
Cancer Research UK (CRUK) raises five hundred million pounds a year for research and drug discovery into any and all of the two hundred plus types of cancer. The charity is extremely well integrated into U.K. culture, and uniquely English in that the donations are mostly small and come from all corners of society. A third of CRUK’s funding comes from donations averaging £10 or less.
Allan Jordan is head of chemistry for the drug discovery unit of CRUK. On today’s show he says that the democratic funding of the charity gives them a great deal of flexibility to do early stage drug discovery. Whereas a big pharma or biotech has to devote their resources to limited assets, or drugs, CRUK is able to spend more on basic biology research and follow the science into any type or cancer or multiple cancers.
There are very few conditions,” says Allan about his drug discovery unit in Manchester. "We don’t have to be specific about any particular disease area; we don’t have to be experts in one disease at the expense of all others. We can tap into that UK-wide expertise and network that can help us understand the biology.”
How is the charity working with the UK's national healthcare system? And does Allan hear the same kind of skepticism that we hear in the U.S. about precision medicine in oncology?